Phase i study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2334-2343

  Weiss, Glen J ^a   Hidalgo, Manuel ^b   Borad, Mitesh J ^a,f   Laheru, Daniel ^b   Tibes, Raoul ^a,f   Ramanathan, Ramesh K ^a   Blaydorn, Lisa ^a   Jameson, Gayle ^a   Jimeno, Antonio ^b,g   Isaacs, Jeffrey D ^a   Scaburri, Angela ^c   Pacciarini, Maria Adele ^c   Fiorentini, Francesco ^d   Ciomei, Marina ^e   Von Hoff, Daniel D ^a  

^a Virginia G Piper Cancer Center   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Milano International Oncology (MIO)   (Italy)

^d Accelera Srl   (Italy)

^e Medical Oncology   (Italy)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cyclin dependent kinase; Investigational agent; PHA 848125AC; Phase I clinical trial; Tropomyosin receptor kinase A

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PHA 848125AC; PHOSPHOTRANSFERASE; TROPOMYOSIN RECEPTOR KINASE A; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ATAXIA; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SOLID TUMOR; THYMUS CANCER; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; CYCLIN-DEPENDENT KINASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUINAZOLINES; RECEPTOR, TRKA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875505550     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9774-6     Document Type: Article

References (37)

1. Allen SJ, Dawbarn D (2006) Clinical relevance of the neurotro-phins and their receptors. Clinical Science 110:175-191
2. Montano X, Djamgoz MB (2004) Epidermal growth factor, neuro-trophins and the metastatic cascade in prostate cancer. FEBS Lett 571:1-8
3. Ketterer K, Rao S, Friess H, Weiss J, Büchler MW, Korc M (2003) Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res 9:5127-5136
4. Papatsoris AG, Liolitsa D, Deliveliotis C (2007) Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 16:303-309
5. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL et al (1998) Cell cycle-independent death of prostate adenocar-cinoma is induced by the TRK tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4:1887-1898
6. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA (1999) Neurotrophins and TRK receptors in human pancreatic Ductal adenocarcinoma: Expression patterns and effects on in vitro invasive behavior. Int J Cancer 81:417-427
7. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R et al (2009) TRKA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28:1960-1970
8. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B et al (2003) Expression and activation of the nerve growth factor receptor TRKA in serous ovarian carcinoma. Clin Cancer Res 9:2248-2259
9. Pierotti MA, Greco A (2006) Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 232:90-98
10. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18:2699-2711
11. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222-231
12. Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J (2005) Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 92:7-12
13. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36
14. Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10-17
15. Desdouets C, Bréchot C (2000) p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer. Pathol Biol (Paris) 48:203-210
16. Adams PD (2001) Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471: M123-M133
17. Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R et al (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35:25-31, Epub 2003 Aug 17
18. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P (2003) Cdk2 knockout mice are viable. Curr Biol 13:1775-1785
19. Méndez J (2003) Cell proliferation without cyclin E-CDK2. Cell 114(4):398-399
20. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E et al (2004) Mouse development and cell proliferation in the absence of D-cyclins. Cell 118:477-491
21. Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G et al (2009) Identification of N, 1, 4, 4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl) phenyl]amino}-4, 5-dihydro-1H-pyrazolo [4, 3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 52:5152-5163
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M et al (2008) The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat Med 22:214-221
24. Cresta S, SessaC, Del Conte G, Locatelli A, Gallerani E, FiorentiniF, et al. Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedule of administration. J Clin Oncol 28:15 s, 2010 (suppl; abstr 3065)
25. Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG et al (2010) Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 9:2243-2254
26. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N et al (2005) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23:31-37
27. Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17:313-320
28. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999
29. Brown JR (2005) Chronic lymphocytic leukemia: a niche for flavopiridol? Clin Cancer Res 11:3971-3973
30. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C et al (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37, Epub 2006 Dec 19
31. Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS et al (2010) Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol 21:884-894, Epub 2009 Oct 13
32. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, et al. (2011) Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. J Clin Oncol 29: (suppl; abstr 6623)
33. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS et al (2009) Brain targeting of nerve growth factor using poly (buthyl cyanoacrylate) nanopar-ticles. J Drug Target 17(8):564-574
34. Baldi A, Ambrogi V, Mineo D, Mellone P, Campioni M, Citro G et al (2005) Analysis of cell cycle regulator proteins in encapsulated thymomas. Clin Cancer Res 11:5078-5083
35. Arguello F, Alexander M, Sterry J, Tudor G, Smith EM, Kalavar NT et al (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 91:2482-2490
36. Kim DJ, Yang WI, Kim SH, Park IK, Chung KY (2005) Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg 28:611-616
37. Ma WY, Murata E, Ueda K, Kuroda Y, Cao MH, Abe M, et al. A synthetic cell-penetrating peptide antagonizing TrkA function suppresses neuropathic pain in mice. J Pharmacol Sci 2010;114:79-84. Epub 2010 Aug 11.